| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/25/1995 | CN1097736A Novel antiarrhythmic agents I |
| 01/25/1995 | CN1097735A Derivative of fatty acid and pharmaceutical composition containg same |
| 01/25/1995 | CN1097727A Octahydrophenanthrene derivatives octahydrophenanthrenderivate |
| 01/25/1995 | CN1097616A Cosmetics or pharmaceutical composition prepared from polyphenol and material obtained from ginkgo |
| 01/25/1995 | CN1097603A Recipe of Fumailing for curing arrhythmic coronary heart disease and producing method |
| 01/25/1995 | CN1097598A Vitamin micro-element purine pyrimidine dinucleotide nutrient product and producing method |
| 01/25/1995 | CN1097595A Coated pharmaceutical preparation |
| 01/25/1995 | CN1027507C Sulfonyl compounds and process for preparing same |
| 01/25/1995 | CN1027506C New 2,9-disubstituted-4H-pyrido(1,2-A) pyrimidin-4-ones |
| 01/25/1995 | CN1027504C Imidazolyl-alkenoic acids |
| 01/25/1995 | CN1027503C Crystalline salt of 4-(di-n-propyl) amino-6-aminocarbonyl-1,3,4,5-tetrahydrohbonz|cd¨indole |
| 01/24/1995 | US5384423 3-cycloalkyl-propanamides |
| 01/24/1995 | US5384408 Nervous system disorders such as Alzheimer*s and senility |
| 01/24/1995 | US5384405 Zinc reduction of nitrobenzoate to hydroxylamine then reduction with isothiocyanate |
| 01/24/1995 | US5384399 Oxazinone compounds for the preparation of taxol |
| 01/24/1995 | US5384398 High molecular mass N,O-sulphated heparosans, process for their preparation and the pharmaceutical compositions which contain them |
| 01/24/1995 | US5384332 Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives |
| 01/24/1995 | US5384330 Pharmaceutically active 1,2,4-triamino-benzene derivatives, processes for their preparation and pharmaceutical compositions containing them |
| 01/24/1995 | US5384327 Anticonvulsant sorbopyranose sulfamates |
| 01/24/1995 | US5384326 Bactericides, fungicides |
| 01/24/1995 | US5384323 Stabilized dopaminergic compositions |
| 01/24/1995 | US5384322 Nitrogen-containing bicyclic compounds and pharmaceutical compositions thereof |
| 01/24/1995 | US5384320 N-hydroxyurea derivatives which inhibit lipoxygenase |
| 01/24/1995 | US5384319 Aminoalkylphenyl compounds |
| 01/24/1995 | US5384316 4,16-diazatetracyclo[23.3.1.1.Hu 14,17=b . 0 Hu 4,9 triaconta-16,19-diene-2,3,10-trione derivatives |
| 01/24/1995 | US5384314 Acne; gland and skin disorders |
| 01/24/1995 | US5384310 2'-fluoro-2-haloarabinoadinosines and their pharmaceutical compositions |
| 01/24/1995 | US5384128 Nontoxic, nonionic surfactants and hypophilic-lipophilic balance number |
| 01/24/1995 | US5384127 Complex with diaminocyclohexane, antitumor agents |
| 01/24/1995 | US5384126 Coloring grey hair, preventing hair loss |
| 01/24/1995 | US5384121 Method for the extraction of sesquiterpene lactones |
| 01/24/1995 | US5384119 Respiratory system disorders, antiarthritic agents |
| 01/24/1995 | US5384116 Synthetic melanin as a sunscreen and tanning agent |
| 01/24/1995 | US5383848 Iontophoretic administration of drugs |
| 01/24/1995 | CA2128560A1 Substituted piperazines, their preparation process and pharmaceutical compositions containing them |
| 01/24/1995 | CA2128288A1 Fatty acid compositions having anti-inflammatory properties |
| 01/24/1995 | CA2038410C Tenidap as an inhibitor of the release of elastage by neutrophils |
| 01/24/1995 | CA2038409C Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase |
| 01/24/1995 | CA1334100C Benzocycloheptene compositions, process for their preparation thereof and pharmaceutical compositions holding same |
| 01/24/1995 | CA1334095C Aroyl urea and carbamic acid derivatives |
| 01/24/1995 | CA1334094C Benzopyran derivatives |
| 01/24/1995 | CA1334092C Angiotensin ii receptor blocking imidazoles |
| 01/24/1995 | CA1334075C Therapeutic use of serotonin antagonists |
| 01/24/1995 | CA1334074C Pharmaceutical composition containing high drug load and method for preparing same |
| 01/23/1995 | CA2128464A1 Bicyclic heterocyclic compounds, pharmaceutical preparations containing these compounds and processes for their preparation |
| 01/23/1995 | CA2128376A1 Parathyroid hormone and raloxifene for increasing bone mass |
| 01/23/1995 | CA2128348A1 Glycoprotein iib/iiia antagonists |
| 01/22/1995 | CA2128116A1 Tris carbamic acid esters: inhibitors of cholesterol absorption |
| 01/21/1995 | CA2128354A1 Pharmaceutical compositions for the prevention and/or treatment of gastrointestinal diseases including ulcer |
| 01/21/1995 | CA2128283A1 (thia)cycloalkyl¬b|indoles, their preparation process and pharmaceutical compositions containing them |
| 01/20/1995 | EP0643696A4 Azavesamicols. |
| 01/20/1995 | CA2128046A1 Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof |
| 01/19/1995 | WO1995002069A1 Oligonucleotide modulation of protein kinase c |
| 01/19/1995 | WO1995002057A1 Protein tyrosine kinase and ligands thereof |
| 01/19/1995 | WO1995002051A2 A pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms |
| 01/19/1995 | WO1995001981A1 Novel substance dc114-a1 |
| 01/19/1995 | WO1995001980A1 Bicyclic tetrahydro pyrazolopyridines |
| 01/19/1995 | WO1995001979A1 Novel (1-heteroazolyl-1-heterocyclyl)alkane derivatives and their use as neuroprotective agents |
| 01/19/1995 | WO1995001978A1 Process for thiopyrans |
| 01/19/1995 | WO1995001977A1 Magnesium omeprazole |
| 01/19/1995 | WO1995001976A1 Indoline derivatives as 5ht2c antagonists |
| 01/19/1995 | WO1995001974A1 Piperidinyl substituted methanoanthracenes as d1/d2-antagonists and 5ht2-serotanin-antagonists |
| 01/19/1995 | WO1995001972A1 Heme binding compounds and use thereof |
| 01/19/1995 | WO1995001968A1 Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclyl)methylamine derivatives |
| 01/19/1995 | WO1995001967A1 Novel (1-phenyl-1-heterocyclyl)alkane derivatives and their use as neuroprotective agents |
| 01/19/1995 | WO1995001965A1 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives as 5ht1a ligands |
| 01/19/1995 | WO1995001960A1 Novel structural analogues of vitamin d |
| 01/19/1995 | WO1995001956A1 Derivatives of valproic and 2-valproenoic acid amides and use as anticonvulsants |
| 01/19/1995 | WO1995001806A1 Pro-cytotoxic drug conjugates for anticancer therapy |
| 01/19/1995 | WO1995001803A1 H2 antagonist-gastrointestinal motility agent combinations |
| 01/19/1995 | WO1995001802A1 Growth differentiation factor-7 |
| 01/19/1995 | WO1995001801A1 Growth differentiation factor-6 |
| 01/19/1995 | WO1995001795A1 H2 antagonist-alginate-antacid combinations |
| 01/19/1995 | WO1995001794A1 Erythromycin derivatives |
| 01/19/1995 | WO1995001793A2 5-ht-3-antagonists as topical medicaments for treatment of peripheral disorders associated with pain |
| 01/19/1995 | WO1995001792A1 H2 antagonist-antihistamine combinations |
| 01/19/1995 | WO1995001791A2 Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases |
| 01/19/1995 | WO1995001790A1 Use of taxoids for treating parasitic diseases |
| 01/19/1995 | WO1995001789A1 Arsenic medicaments for the treatment of chronic fatigue syndrome |
| 01/19/1995 | WO1995001786A1 Pharmaceutical compositions for hardly soluble active substances |
| 01/19/1995 | WO1995001785A1 Pharmaceutical compositions for hardly soluble active substances |
| 01/19/1995 | WO1995001784A1 H2 antagonist-sucralfate-antiflatulent combinations |
| 01/19/1995 | WO1995001783A1 New pharmaceutical formulation |
| 01/19/1995 | WO1995001782A2 Method for making freeze dried drug dosage forms |
| 01/19/1995 | WO1995001780A1 H2 antagonist-alginate combinations |
| 01/19/1995 | WO1995001767A1 Monolithic matrix transdermal delivery system |
| 01/19/1995 | WO1995001766A1 Method and device for providing nicotine replacement therapy transdermally/transbuccally |
| 01/19/1995 | WO1994023688A3 Cosmetic and medicinal topical preparations |
| 01/19/1995 | DE4324014A1 Process for the production of a composition which can be reconstituted in water |
| 01/19/1995 | DE4323615A1 Compositions to prevent premature ageing of the skin |
| 01/19/1995 | CA2166869A1 Method and device for providing nicotine replacement therapy transdermally/transbuccally |
| 01/19/1995 | CA2166798A1 Pro-cytotoxic drug conjugates for anticancer therapy |
| 01/19/1995 | CA2166781A1 Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases |
| 01/19/1995 | CA2166780A1 Monolithic matrix transdermal delivery system |
| 01/19/1995 | CA2166731A1 H2 antagonist-alginate-antacid combinations |
| 01/19/1995 | CA2166730A1 H2 antagonist-gastrointestinal motility agent combinations |
| 01/19/1995 | CA2166629A1 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives as 5ht1a ligands |
| 01/19/1995 | CA2166624A1 Indoline derivatives as 5ht2c antagonists |
| 01/19/1995 | CA2166222A1 Heme binding compounds and use thereof |
| 01/19/1995 | CA2166058A1 Oligonucleotide modulation of protein kinase c |